Benxiu Malong Jiaonang (苯溴马隆胶囊)苯溴马隆胶囊

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

其化学名为是一种在国家药监局注册认定的药品。该药品含有其化学名为-9702a577等成分。

该药品关联的活性成分包括:其化学名为。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:昆山龙灯瑞迪制药有限公司Chinese legal name: 昆山龙灯瑞迪制药有限公司。

您可以探索含有相同成分的其他药品:其化学名为-9702a577成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 苯溴马隆胶囊) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Manufacturers recorded for this product: 昆山龙灯瑞迪制药有限公司Chinese legal name: 昆山龙灯瑞迪制药有限公司.

Explore other medicines containing the same ingredient: 其化学名为 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 苯溴马隆胶囊Recorded Chinese name: 苯溴马隆胶囊
  • 剂型Dosage form: 胶囊剂Capsules
  • 规格Specification: 50mg*10粒50 mg × 10 capsules

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

生产企业Manufacturer

  • 昆山龙灯瑞迪制药有限公司Chinese legal name: 昆山龙灯瑞迪制药有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H20010790

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H20010790

Manufacturer

Chinese legal name: 昆山龙灯瑞迪制药有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

Keep tightly closed.

Specification

50 mg × 10 capsules

中文说明书原文Original Chinese source label

批准文号

国药准字H20010790

生产企业

昆山龙灯瑞迪制药有限公司(国产)

适应症

主要用于慢性痛风的治疗。也可用于各种原因引起的继发性高尿酸血症,原发性高尿酸血症。

用法用量

成人常用量:由小剂量开始,一日25mg(半片)开始,无不良反应可逐渐递增至一日100mg(2片)。早餐后服,同时加服碳酸氢钠一日3g。

不良反应

1.胃肠反应:恶心及腹部不适等。
2.引起肾结石和肾绞痛。
3.诱发关节炎急性发作。
4.罕见发热、皮疹和肝或肾功能损害。

禁忌

中、重度肾功能损害者及患有肾结石的患者禁用。

注意事项

1.服用过程中应多饮水,碱化尿液。对肾功能下降,血肌酐大于130μmol/L者仍然有效,但必须保持每日尿量在2000ml以上。
2.定期检测肾功能以及血和尿尿酸的变化。
3.必须在痛风性关节炎的急性症状控制后方能应用本品。

贮藏

密闭保存。

规格

50mg*10粒

证据Evidence

  • 批准文号: 国药准字H20010790
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.